Cargando…
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Immune checkpoint inhibitors (ICIs) are emerging as the new standard of care for treating various metastatic cancers. It is known that effective anti-tumor immune responses are associated with a stronger presence of tumor-infiltrating lymphocytes (TILs) in solid tumor tissue. Cancer patients with re...
Autores principales: | Hasan Ali, Omar, Berner, Fiamma, Ackermann, Christoph Jakob, Ring, Sandra Stephanie, Moulin, Alexandre, Müller, Joachim, Markert, Eva, Pop, Oltin Tiberiu, Müller, Stefanie, Diem, Stefan, Hundsberger, Thomas, Flatz, Lukas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889549/ https://www.ncbi.nlm.nih.gov/pubmed/32804246 http://dx.doi.org/10.1007/s00262-020-02693-7 |
Ejemplares similares
-
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
por: Diem, Stefan, et al.
Publicado: (2018) -
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023) -
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients
por: Purde, Mette-Triin, et al.
Publicado: (2021) -
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019) -
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022)